{
  "first_published_at": "2007-10-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON079276", 
  "title": "Botulinum toxin products: rare but serious risk", 
  "tags": "{\"parsed_therapeutic\": [\"neurology\", \"psychiatry\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Neurology\", \"Psychiatry\"]}", 
  "_document_number": 322, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "neurology", 
    "psychiatry"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Botulinum toxin products: rare but serious risk</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: October 2007</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Products that contain botulinum toxin are associated with a risk of serious adverse reactions due to distant spread of toxin-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p><strong>Products that contain botulinum toxin are associated with the risk of serious adverse reactions due to distant spread f toxin</strong></p><p>Four products that contain botulinum toxin are licensed in the UK: Botox, Dysport, NeuroBloc, and Vistabel. Indications include focal spasticity, some types of spasm, and excessive sweating of the axillae (arm pits). Vistabel is indicated only for treatment of vertical frown lines between the eyebrows, where their severity has an important psychological effect on the patient. Botulinum toxins prevent the release of acetylcholine at neuromuscular or other cholinergic junctions and reversibly denervate muscles or eccrine glands.</p><ul>\r\n\t\t\t<li>Spread reactions&mdash;including muscle weakness, dysphagia, and aspiration&mdash;have been reported rarely with all products that contain botulinum toxin</li>\r\n\t\t\t<li>Extreme caution is needed on administration of products that contain botulinum toxin to patients who have neurological disorders, or a history of dysphagia or aspiration</li>\r\n\t\t\t<li>Only physicians with appropriate experience (including use of the required equipment) should administer products that contain botulinum toxin</li>\r\n\t\t\t<li>Patients or caregivers should be informed about the risk of spread of toxin, and should be advised to seek immediate medical care if problems with swallowing or speech develop, or if respiratory symptoms arise</li>\r\n\t\t\t<li>Units of botulinum toxin are not interchangeable from one product to another</li>\r\n\t\t\t<li>Recommended administration techniques and specific dosing guidance (including the recommendation to use the minimum effective dose and titrate according to individual need) should be followed</li></ul><p>For further information see&nbsp;<a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON2031602\" target=\"_blank\"><font color=\"#333333\">Letters sent to healthcare professionals, June 2007</font></a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update October 2007; Vol 1, Issue 3: 10.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p><strong>Products that contain botulinum toxin are associated with the risk of serious adverse reactions due to distant spread f toxin</strong></p><p>Four products that contain botulinum toxin are licensed in the UK: Botox, Dysport, NeuroBloc, and Vistabel. Indications include focal spasticity, some types of spasm, and excessive sweating of the axillae (arm pits). Vistabel is indicated only for treatment of vertical frown lines between the eyebrows, where their severity has an important psychological effect on the patient. Botulinum toxins prevent the release of acetylcholine at neuromuscular or other cholinergic junctions and reversibly denervate muscles or eccrine glands.</p><ul>\r\n\t\t\t<li>Spread reactions&#8212;including muscle weakness, dysphagia, and aspiration&#8212;have been reported rarely with all products that contain botulinum toxin</li>\r\n\t\t\t<li>Extreme caution is needed on administration of products that contain botulinum toxin to patients who have neurological disorders, or a history of dysphagia or aspiration</li>\r\n\t\t\t<li>Only physicians with appropriate experience (including use of the required equipment) should administer products that contain botulinum toxin</li>\r\n\t\t\t<li>Patients or caregivers should be informed about the risk of spread of toxin, and should be advised to seek immediate medical care if problems with swallowing or speech develop, or if respiratory symptoms arise</li>\r\n\t\t\t<li>Units of botulinum toxin are not interchangeable from one product to another</li>\r\n\t\t\t<li>Recommended administration techniques and specific dosing guidance (including the recommendation to use the minimum effective dose and titrate according to individual need) should be followed</li></ul><p>For further information see&#160;<a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON2031602\" target=\"_blank\">Letters sent to healthcare professionals, June 2007<font color=\"#333333\">Letters sent to healthcare professionals, June 2007</font></a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update October 2007; Vol 1, Issue 3: 10.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2007-10-01", 
  "date_last_modified": "2010-10-01", 
  "_assets": [], 
  "_item_id": 322, 
  "summary": "", 
  "body": "Article date: October 2007\n\nProducts that contain botulinum toxin are associated with the risk of serious adverse reactions due to distant spread f toxin\n\nFour products that contain botulinum toxin are licensed in the UK: Botox, Dysport, NeuroBloc, and Vistabel. Indications include focal spasticity, some types of spasm, and excessive sweating of the axillae (arm pits). Vistabel is indicated only for treatment of vertical frown lines between the eyebrows, where their severity has an important psychological effect on the patient. Botulinum toxins prevent the release of acetylcholine at neuromuscular or other cholinergic junctions and reversibly denervate muscles or eccrine glands.  \n  \n  * Spread reactions—including muscle weakness, dysphagia, and aspiration—have been reported rarely with all products that contain botulinum toxin  \n  * Extreme caution is needed on administration of products that contain botulinum toxin to patients who have neurological disorders, or a history of dysphagia or aspiration  \n  * Only physicians with appropriate experience (including use of the required equipment) should administer products that contain botulinum toxin  \n  * Patients or caregivers should be informed about the risk of spread of toxin, and should be advised to seek immediate medical care if problems with swallowing or speech develop, or if respiratory symptoms arise  \n  * Units of botulinum toxin are not interchangeable from one product to another  \n  * Recommended administration techniques and specific dosing guidance (including the recommendation to use the minimum effective dose and titrate according to individual need) should be followed  \n  \nFor further information see [Letters sent to healthcare professionals, June 2007Letters sent to healthcare professionals, June 2007](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON2031602)\n\n \n\nArticle citation: Drug Safety Update October 2007; Vol 1, Issue 3: 10.\n"
}